Pancreatic Cancer Research

ResearcherThe University of TokyoActive in the last 2 years

Suguru Mizuno

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-7216-2269; OpenAlex author ID A5043841395. Sources: OpenAlex.

Their work

Papers
32 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 8 papers · 2014: 4 papers · 2015: 3 papers · 2016: 2 papers · 2017: 3 papers · 2018: 2 papers · 2019: 3 papers · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper

Papers 32

  1. Hemorrhage into the bile duct after endoscopic ultrasound-guided fine needle aspiration for pancreatic cancer. First author DOI 10.1055/a-2313-3991↗
  2. A phase I study of intraperitoneal paclitaxel combined with gemcitabine plus nab-paclitaxel for pancreatic cancer with peritoneal metastasis. Co-author DOI 10.1007/s10637-020-00982-7↗
  3. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel. Co-author DOI 10.1007/s10637-020-01022-0↗
  4. Screening Strategy of Pancreatic Cancer in Patients with Diabetes Mellitus. Co-author DOI 10.3390/diagnostics10080572↗
  5. A phase II trial of gemcitabine, S-1 and LV combination (GSL) therapy in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s10637-018-0691-9↗
  6. Diagnostic yield of the plasma free amino acid index for pancreatic cancer in patients with diabetes mellitus. Co-author DOI 10.1016/j.pan.2019.07.002↗
  7. Development of pancreatic cancer during observation for hepatocellular carcinoma: A retrospective cohort study. Co-author DOI 10.4103/sjg.sjg_56_19↗
  8. A phase II trial of gemcitabine, S-1 and LV combination (GSL) neoadjuvant chemotherapy for patients with borderline resectable and locally advanced pancreatic … Co-author DOI 10.1007/s12032-018-1158-8↗
  9. A Multicenter Open-Label Randomized Controlled Trial of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001079↗
  10. Development of pancreatic cancer is predictable well in advance using contrast-enhanced CT: a case-cohort study. Co-author DOI 10.1007/s00330-017-4895-8↗
  11. The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer: A Prospective Cohort Study. Co-author DOI 10.1097/mpa.0000000000000767↗
  12. Thromboembolisms in Advanced Pancreatic Cancer: A Retrospective Analysis of 475 Patients. Co-author DOI 10.1097/mpa.0000000000000889↗
  13. Intravenous and intraperitoneal paclitaxel with S-1 for treatment of refractory pancreatic cancer with malignant ascites. Co-author DOI 10.1007/s10637-016-0369-0↗
  14. Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer. Co-author DOI 10.1016/j.ejca.2016.05.016↗
  15. The inhibition of renin-angiotensin system in advanced pancreatic cancer: an exploratory analysis in 349 patients. Co-author DOI 10.1007/s00432-014-1873-2↗
  16. Pancreatic cancer with malignant ascites: clinical features and outcomes. Co-author DOI 10.1097/mpa.0000000000000290↗
  17. [IPMN and pancreatic cyst as high risk of pancreatic cancer]. Co-author DOI 10.11405/nisshoshi.112.1474↗
  18. A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer. Co-author DOI 10.1007/s00280-014-2563-0↗
  19. Intravenous and intraperitoneal paclitaxel with S-1 for refractory pancreatic cancer with malignant ascites: an interim analysis. Co-author DOI 10.1007/s12029-014-9603-1↗
  20. Smoking, family history of cancer, and diabetes mellitus are associated with the age of onset of pancreatic cancer in Japanese patients. Co-author DOI 10.1097/mpa.0000000000000158↗
  21. Risk factors for covered metallic stent migration in patients with distal malignant biliary obstruction due to pancreatic cancer. Co-author DOI 10.1111/jgh.12602↗
  22. Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monoth… Co-author DOI 10.1007/s00280-012-1981-0↗
  23. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer. Co-author DOI 10.1007/s00280-013-2278-7↗
  24. A retrospective analysis of early CA19‑9 change in salvage chemotherapy for refractory pancreatic cancer. Co-author DOI 10.1007/s00280-013-2313-8↗
  25. Risk factors and early signs of pancreatic cancer in diabetes: screening strategy based on diabetes onset age. Co-author DOI 10.1007/s00535-012-0622-z↗
  26. A multicenter phase II trial of gemcitabine and candesartan combination therapy in patients with advanced pancreatic cancer: GECA2. Co-author DOI 10.1007/s10637-013-9972-5↗
  27. Diabetes is a useful diagnostic clue to improve the prognosis of pancreatic cancer. Co-author DOI 10.1016/j.pan.2013.03.013↗
  28. Clinical outcomes of chemotherapy for diabetic and nondiabetic patients with pancreatic cancer: better prognosis with statin use in diabetic patients. Co-author DOI 10.1097/mpa.0b013e31825de678↗
  29. Risk for mortality from causes other than pancreatic cancer in patients with intraductal papillary mucinous neoplasm of the pancreas. Co-author DOI 10.1097/mpa.0b013e318270ea97↗
  30. Phase I trial of gemcitabine and candesartan combination therapy in normotensive patients with advanced pancreatic cancer: GECA1. Co-author DOI 10.1111/j.1349-7006.2012.02311.x↗
  31. Duodenal invasion is a risk factor for the early dysfunction of biliary metal stents in unresectable pancreatic cancer. Co-author DOI 10.1016/j.gie.2011.04.046↗
  32. Gemcitabine and oxaliplatin combination chemotherapy for patients with refractory pancreatic cancer. Co-author DOI 10.1159/000328767↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kazuhiko Koike · 31 shared papers, 2011–2021 · strength 1.48
  2. Yousuke Nakai · 31 shared papers, 2011–2021 · strength 1.48
  3. Hiroyuki Isayama · 30 shared papers, 2011–2021 · strength 1.37
  4. Hirofumi Kogure · 29 shared papers, 2011–2021 · strength 1.33
  5. Naminatsu Takahara · 24 shared papers, 2011–2021 · strength 1.19
  6. Minoru Tada · 26 shared papers, 2011–2019 · strength 1.03
  7. Tsuyoshi Hamada · 20 shared papers, 2011–2021 · strength 0.99
  8. Kei Saito · 13 shared papers, 2014–2021 · strength 0.84
  9. Hideaki Ijichi · 19 shared papers, 2012–2021 · strength 0.78
  10. Kazunaga Ishigaki · 10 shared papers, 2015–2021 · strength 0.71
  11. Tomotaka Saito · 9 shared papers, 2014–2021 · strength 0.63
  12. Saburo Matsubara · 12 shared papers, 2011–2019 · strength 0.52
  13. Takashi Sasaki · 15 shared papers, 2011–2015 · strength 0.45
  14. Koji Miyabayashi · 14 shared papers, 2012–2015 · strength 0.43
  15. Dai Mohri · 12 shared papers, 2011–2017 · strength 0.40
  16. Satoshi Mochida · 1 shared paper, 2024 · strength 0.36
  17. Kazuya Miyaguchi · 1 shared paper, 2024 · strength 0.36
  18. Naoki Sasahira · 13 shared papers, 2011–2015 · strength 0.36
  19. Keisuke Yamamoto · 10 shared papers, 2011–2015 · strength 0.29
  20. Kazumichi Kawakubo · 10 shared papers, 2011–2015 · strength 0.27
  21. Tsuyoshi Takeda · 4 shared papers, 2015–2019 · strength 0.24
  22. Yukari Suzuki · 2 shared papers, 2020–2021 · strength 0.20
  23. Takashi Sasaki · 4 shared papers, 2011–2019 · strength 0.16
  24. Wataru Gonoi · 2 shared papers, 2017–2019 · strength 0.15
  25. Yasuyuki Seto · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.